Spots Global Cancer Trial Database for A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

Official Title: A Pilot Proof of Mechanism Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPPs), in Patients With Pancreatic Cancer

Study ID: NCT04123574

Conditions

Cancer of Pancreas

Cancer of the Pancreas

Neoplasms, Pancreatic

Pancreas Cancer

Pancreatic Cancer

Interventions

Talabostat Mesylate

Study Description

Brief Summary: A study to assess the biochemical and immunomodulatory effects of BXCL701 in pancreatic cancer.

Detailed Description: This is a Phase 0 or "window of opportunity" study where paired specimen analysis, taken before and after drug exposure, will permit the evaluation of target modulation and assessment of immune effector cell infiltration into the tumor and the generation of relevant immune cytokines. In this study, BXCL701 will be administered at a dose of 0.3 mg, twice daily for a total daily dose of 0.6mg (the previously defined maximum tolerated dose \[MTD\] of the drug), to all patients for a short period of 14 days. This study is designed to assess the biochemical and immunomodulatory effects of BXCL701 in pancreatic cancer.